The content on this site is intended for healthcare professionals only
Dr Mike Dennis speaks with ecancertv at BSH 2016 about the most recent results of the multinational AML17 trial.
Using varying dosages of duanorubicin across the randomized trial, Dr Dennis reports a maximum tolerated dose of 60mg, with significant benefits to patient survival.
Most notably, he describes a specific benefit to patients with FLIP3 mutations.
He also reflects on study construction between American, English and European trials, and how to optimise techniques for best patient outcomes.
ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
